Nyrada secures US composition of matter patent for Xolatryp®
Nyrada Inc. (ASX: NYR) has been granted a composition of matter patent for Xolatryp®, its lead Transient Receptor Potential Canonical (TRPC) ion channel inhibitor, in the United States. The patent protects the chemical structure of Xolatryp® and carries a 20-year term from the September 2024 filing date, establishing enforceable US intellectual property protection over the compound at an active stage of clinical development.
When big ASX news breaks, our subscribers know first
What a composition of matter patent means for Nyrada’s IP position
A composition of matter patent is widely regarded as the broadest and most defensible form of pharmaceutical patent protection available. Rather than covering a specific method of use or formulation, it protects the underlying chemical structure of the compound itself.
In practical terms, the granted patent prohibits the unauthorised manufacture, use, sale, or import of Xolatryp® within the United States without Nyrada’s approval. This protection applies to the molecule regardless of the indication it is used for, giving Nyrada a strong IP foundation across its clinical and preclinical programmes.
Global filing strategy adds depth to IP position
The US grant forms part of a broader global patent portfolio being filed by Nyrada across key jurisdictions. Future filings are planned across the following regions:
- United States (granted)
- Australia (to be filed)
- Europe (to be filed)
- Japan (to be filed)
The US represents the lead granted jurisdiction at this stage. Filings for the remaining jurisdictions are yet to be made.
Xolatryp® in active Phase IIa trial for heart attack patients
The patent news is anchored to a compound already progressing through human clinical trials. Phase I, which assessed the safety, tolerability, and pharmacokinetics of Xolatryp®, has been successfully completed.
A Phase IIa trial, known as the PROTECT-MI trial, has since commenced. The trial is designed to assess the safety and preliminary efficacy of Xolatryp® in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Beyond cardioprotection, preclinical data for Xolatryp® spans neuroprotection and oncology models, though these remain at a preclinical stage.
PROTECT-MI trial activation at Nepean Hospital in NSW marked the programme’s transition from regulatory planning to active patient recruitment, with preclinical data showing up to 86% cardioprotection and a 90% reduction in arrhythmias underpinning the biological rationale for the 100-patient, double-blind design.
IP protection locked in as clinical trial advances
The timing of the US patent grant is notable. Xolatryp® now holds enforceable IP protection in its most commercially significant market as the Phase IIa PROTECT-MI trial is actively underway. Strong patent protection of this kind is generally a prerequisite for licensing, partnership, or commercialisation discussions, and may position Nyrada more attractively to potential partners as clinical data continues to accumulate.
The Xolatryp cardioprotection study in a doxorubicin model delivered statistically significant protection across four cardiac measures, with functional outcomes comparable to dexrazoxane, the only currently approved cardioprotective agent, while also demonstrating a 57% tumour volume reduction that positions Xolatryp as a potential dual-action oncology adjunct.
Key points for investors to consider:
- 20-year patent term running from the September 2024 filing date
- Composition of matter protection, the broadest category of pharmaceutical IP
- Global portfolio planned across four key jurisdictions: US (granted), Australia, Europe, and Japan
- Phase IIa PROTECT-MI trial actively underway following successful Phase I completion
| Detail | Information |
|---|---|
| Patent type | Composition of matter |
| Jurisdiction (granted) | United States |
| Patent term | 20 years from September 2024 filing date |
| Planned jurisdictions | Australia, Europe, Japan |
| Clinical trial stage | Phase IIa (PROTECT-MI) — active |
Don’t Miss the Next Healthcare Breakthrough
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts now.